FDA Breakthrough Device Designation Granted to RecovryAI’s Patient-Facing Clinical AI

RecovryAI has secured U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its Virtual Care Assistants (VCAs)—physician-prescribed, patient-facing clinical artificial intelligence (AI) designed to support patients during post-operative recovery.

The designation, reserved for medical devices that address serious conditions and demonstrate the potential to meaningfully improve existing standards of care, enables earlier and more frequent engagement with the FDA while maintaining the full requirements for demonstrating safety and reliability. The milestone coincides with RecovryAI’s emergence from stealth after more than two years of product development and clinical evaluation.

Post-surgical care in the United States has fundamentally shifted outside the hospital. More than 80% of procedures are now performed on a same-day basis, leaving patients to recover at home during their longest and least-supervised care phase. Early signs of complications can go unnoticed, discharge instructions are often forgotten, and providers lack continuous visibility into patient recovery between discharge and follow-up visits, increasing the risk of avoidable emergency department visits, readmissions, and delayed intervention. At the same time, care teams are burdened with high volumes of routine patient questions and recovery updates, limiting their capacity to focus on higher-acuity cases.

RecovryAI’s Virtual Care Assistants are designed to extend continuity of care from hospital discharge into recovery at home. VCAs are physician-prescribed AI that deliver procedure-specific recovery guidance based on established clinical guidelines and escalate deviations from expected recovery patterns to the prescribing care team with full clinical context. RecovryAI’s initial Virtual Care Assistant focuses on total joint arthroplasty, with the architecture designed to support procedure-specific VCAs across procedural domains, subject to regulatory authorization.

RecovryAI is pursuing FDA authorization under a novel Class II pathway for patient-facing Software as a Medical Device (SaMD). The company has engaged the FDA through the pre-submission process since 2024 to align on clinical evidence requirements, with full submission expected later this year. If authorized, this decision would establish a new device classification and the special controls governing future devices in this category.

“Healthcare innovation will not scale without trust. Most healthcare AI today lives in two lanes: clinician-facing tools like decision support and ambient documentation, and consumer health applications,” RecovryAI Co-Founder/CEO Scott Walchek said. “Patient-facing AI inside the care pathway is different. It guides behavior and carries clinical responsibility. In this lane, trust is underwritten by FDA authorization. Without it, there’s no durable basis for accountability, reimbursement, or real scale. From day one, we built within a regulatory framework and embraced the rigor clinical deployment requires.”

RecovryAI is currently conducting a pivotal clinical study evaluating the safety and system behavior of its Virtual Care Assistants in total joint arthroplasty recovery. The multi-site study includes OrthoArizona, one of the nation’s largest orthopedic practices, and Mercy Medical Center in Baltimore, among other participating sites. Data from the company’s limited pilot phase showed that VCA system behavior generally aligned with physician judgment, supporting advancement into the pivotal study.

“Deploying generative AI in a regulated clinical environment requires a structured medical reasoning framework,” RecovryAI Co-Founder/Chief Science Officer Dr. Richard Watson stated. “We designed our platform to continuously evaluate patient-reported information against expected recovery trajectories, deliver procedure-specific guidance when recovery is progressing appropriately, and escalate deviations to the prescribing physician’s care team with the complete patient interaction history and relevant clinical context. That architecture allows the AI to manage routine, low-acuity concerns while ensuring that clinicians retain oversight and exercise final medical judgment.”

RecovryAI is led by a team with deep clinical, regulatory, and technology expertise. Dr. Watson holds more than 100 medical device patents and has led three prior FDA submissions. He and Co-Founder/Chief Medical Officer Dr. Martin Sellberg, a 30-year emergency medicine veteran, previously founded and successfully exited a medical device company. Walchek has four decades of experience building and exiting venture-backed technology companies across multiple industries, and Chief Product Officer Jesse Thomas adds more than a decade of healthcare technology product leadership.

RecovryAI develops FDA-regulated Virtual Care Assistants that support patients during post-procedure recovery after hospital discharge. Physician-prescribed, VCAs deliver recovery guidance and escalate deviations from expected recovery patterns to the prescribing care team with full clinical context. Starting with total joint arthroplasty, RecovryAI is developing procedure-specific Virtual Care Assistants across surgical domains, subject to regulatory authorization. The company is headquartered in San Francisco.